ArticleFrontiers in microbiology2025
Effect and mechanism of
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Intestinal Multi-Target Mechanisms of Natural Active Substances in Hyperuricemia Alleviation: Recent Progress.Nutrients · 2026Review
- Exopolysaccharides fromFoods (Basel, Switzerland) · 2026Article
- Research progress on the correlation between gut microbiota and the occurrence of hyperuricemia.Frontiers in microbiology · 2026Review
- Uricase deficiency in rats results in a variety of metabolic disorders, addition to gouty nephropathy.PloS one · 2025Article
- Advances in Traditional Chinese Medicine for the treatment of hyperuricemia and associated diseases: pathogenesis, mechanisms, and future directions.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hyperuricemia (HUA) is characterized by metabolic abnormalities in purine metabolism, leading to an excessive accumulation of uric acid in the bloodstream. This condition is not only prevalent but also significantly linked to the exacerbation of various chronic diseases, including renal impairment. Notably, asymptomatic hyperuricemia is frequently associated with inflammatory responses and alterations in intestinal microbiota. Thus, it is imperative to explore effective therapeutic interventions for HUA to mitigate its associated health risks. Methods: The present study aimed to elucidate the protective effects of Results: The findings demonstrated that PSP significantly decreased serum uric acid (UA) levels and alleviated renal dysfunction through modulation of xanthine oxidase (XOD) and adenosine deaminase (ADA) serum concentrations and the expression of renal transporters, namely glucose transporter protein 9 (GLUT9), urate transporter 1 (URAT1), ATP-binding cassette superfamily member 2 (ABCG2), and organic anion transporter 1 (OAT1). Furthermore, PSP exhibited notable anti-inflammatory properties, reflected in the reduced levels of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). Conclusion: In summary, the present study substantiates the therapeutic potential of PSP in treating hyperuricemia through its dual action of lowering uric acid levels and imparting anti-inflammatory effects. The observed modulation of gut microbiota further supports the role of PSP in maintaining metabolic homeostasis. Future investigations should focus on the clinical applicability of PSP and elucidate the mechanisms underlying its beneficial impacts on hyperuricemia and associated metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.